IN8bio, Inc. Common Stock (INAB) is a publicly traded Healthcare sector company. As of November 5, 2026, INAB trades at $0.83 with a market cap of $9.18M and a P/E ratio of -0.85. INAB moved -10.83% today. Year to date, INAB is -66.28%; over the trailing twelve months it is -48.90%. Its 52-week range spans $0.81 to $7.50. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces INAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for INAB, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $0.83 |
| Market Cap | $9.18M |
| P/E Ratio | -0.85 |
| EPS | $-1.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.50 |
| 52-Week Low | $0.81 |
| Volume | 41.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $534.00K |
| Net Income | $-18.67M |
| Gross Margin | 0.00% |
2 analysts cover INAB: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.